Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics

Pharmacogenomics

Volumn 3, Issue 4, 2002, Pages 485-492

  Mattison, Lori K ^a   Soong, Richie ^a   Diasio, Robert B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

5 FU; Dihydropyrimidine dehydrogenase; Dihydropyrimidine dehydrogenase deficiency; DPYD; Pharmacogenetic; Pharmacogenomic

Indexed keywords

BIOLOGICAL MARKER; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; OXIDOREDUCTASE;

ALLELE; CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; ONCOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; GENETIC MARKER; GENETICS; GENOMICS; METABOLISM;

ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; GENETIC MARKERS; GENOMICS; HUMAN; OXIDOREDUCTASES; PHARMACOGENETICS; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS;

EID: 0036020649     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.4.485     Document Type: Review

References (61)

1. Clinical pharmacology of 5-fluorouracil
2. Metabolism of pyrimidine analogues and their nucleosides
3. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea
4. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms
5. Nomenclature for human DPYD alleles
6. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
7. Population study of dihydropyrimidine dehydrogenase in cancer patients
8. Colorectal tumours responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase
9. Fluorinated pyrimidines. A new class of tumour inhibitory compounds
10. Purification and properties of dihydrothymine dehydrogenase from rat liver
11. Purification and characterization of dihydropyrimidine dehydrogenase from pig liver
12. Purification and characterization of dihydropyrimidine dehydrogenase from human liver
13. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization
14. Structural organization of the human dihydropyrimidine dehydrogenase gene
15. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
16. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving continuous infusion
17. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter
18. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
19. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
20. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile
21. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
22. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil
23. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
24. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes
25. Semiautomated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
26. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
27. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver
28. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
29. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
30. Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation
31. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
32. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G→A point mutation
33. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
34. Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes
35. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls
36. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
37. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype
38. Autoregulation of 5-fluorouracil metabolism
39. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
40. Response to fluorouracil therapy in cancer patients: The role of tumoural dihydropyrimidine dehydrogenase activity
41. Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma and correlation between immunohistochemical score and protein level or messenger RNA expression
42. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels
43. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
44. Relationship between intratumoural dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer
45. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer
46. Dihydropyrimidine dehydrogenase, multi-drug resistance-associated protein and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells
47. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumour effect of 5-fluorouracil on human tumour xenografts in nude mice
48. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil
49. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
50. Intratumoural expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy
51. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1)
52. Dihydropyrimidine dehydrogenase activity of cancerous and noncancerous tissues in liver and large intestine
53. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer
54. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer
55. Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene
56. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
57. Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli
58. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil
59. Dihydropyrimidine dehydrogenase (DPD) deficiency: Identification and expression of missense mutations C29R, R886H and R235W
60. Dihydropyrimidine dehydrogenase deficiency: A novel mutation and expression of missense mutations in E. coli
61. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity